A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.

@article{Wu2018ACE,
  title={A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.},
  author={Yishuo Wu and Hongjie Yu and S{\'i}qun Lilly Zheng and Rong Na and Mufaddal Mamawala and Tricia Landis and Kathleen E. Wiley and Jacqueline Petkewicz and Sameep Shah and Zhuqing Shi and Kristian R Novakovic and Michael S. McGuire and Charles B. Brendler and Qiang Ding and Brian T. Helfand and Herbert Ballentine Carter and Kathleen A. Cooney and William B Isaacs and Jianfeng Xu},
  journal={The Prostate},
  year={2018},
  volume={78 8},
  pages={
          607-615
        }
}
BACKGROUND Germline mutations in CHEK2 have been associated with prostate cancer (PCa) risk. Our objective is to examine whether germline pathogenic CHEK2 mutations can differentiate risk of lethal from indolent PCa. METHODS A case-case study of 703 lethal PCa patients and 1455 patients with low-risk localized PCa of European, African, and Chinese origin was performed. Germline DNA samples from these patients were sequenced for CHEK2. Mutation carrier rates and their association with lethal… CONTINUE READING

Figures, Tables, and Topics from this paper.

Explore Further: Topics Discussed in This Paper